{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:27:26Z","timestamp":1776212846885,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clgc.2019.01.007","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T22:39:19Z","timestamp":1547851159000},"page":"e461-e471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5065-0445","authenticated-orcid":false,"given":"Ashwin S.","family":"Balakrishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Samuel L.","family":"Washington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxwell V.","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sima P.","family":"Porten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.01.007_bib1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2019.01.007_bib3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Gu\u00e9rin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib4","first-page":"1946","article-title":"Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder","volume":"162","author":"Leblanc","year":"1999","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1464-410X.2009.08654.x","article-title":"Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?","volume":"104","author":"Dobruch","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2019.01.007_bib6","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bju.12245","article-title":"Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy","volume":"113","author":"Ark","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2019.01.007_bib7","first-page":"490","article-title":"Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy","volume":"166","author":"Dutta","year":"2001","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.eururo.2012.08.064","article-title":"Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer","volume":"63","author":"Thomas","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib9","first-page":"86","article-title":"Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1200\/JCO.2014.57.6967","article-title":"Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: a meta-analysis of 15,215 patients","volume":"33","author":"Martin-Doyle","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.01.007_bib11","first-page":"1","article-title":"American Urological Association (AUA) Guideline American Urological Association Non-Muscle Invasive Bladder Cancer","author":"Daneshmand","year":"2016","journal-title":"AUA Clin Guidel"},{"key":"10.1016\/j.clgc.2019.01.007_bib12","series-title":"Bladder Cancer (Version 5.2018)","year":"2018"},{"key":"10.1016\/j.clgc.2019.01.007_bib13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib14","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1002\/cncr.26198","article-title":"Compliance with guidelines for patients with bladder cancer: variation in the delivery of care","volume":"117","author":"Chamie","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.01.007_bib15","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1245\/s10434-013-2901-1","article-title":"Comparison of cases captured in the national cancer data base with those in population-based central cancer registries","volume":"20","author":"Lerro","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clgc.2019.01.007_bib16","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/cncr.25007","article-title":"Patterns of care for early stage bladder cancer","volume":"116","author":"Strope","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.01.007_bib17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2019.01.007_bib18","first-page":"90","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A\u00a0systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2019.01.007_bib20","series-title":"2018 Qualified Clinical Data Registry Measures Checklist","year":"2018"},{"key":"10.1016\/j.clgc.2019.01.007_bib21","article-title":"Utilization of bacillus Calmette-Gu\u00e9rin for nonmuscle invasive bladder cancer in an era of bacillus Calmette-Gu\u00e9rin supply shortages [e-pub ahead of print]","author":"Khanna","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2019.01.007_bib22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2009.08.024","article-title":"An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer","volume":"57","author":"Kulkarni","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib23","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.6004\/jnccn.2016.0150","article-title":"High-risk of adverse pathologic features in patients with clinical T1 high-grade bladder cancer undergoing radical cystectomy","volume":"14","author":"Matulewicz","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2019.01.007_bib24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2019.01.007_bib25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2011.10.026","article-title":"A\u00a0new and highly prognostic system to discern T1 bladder cancer substage","volume":"61","author":"Van Rhijn","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/MOU.0000000000000089","article-title":"Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer","volume":"24","author":"Porten","year":"2014","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.eururo.2006.11.004","article-title":"Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy","volume":"51","author":"Nielsen","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib28","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/bjc.2013.106","article-title":"Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients","volume":"108","author":"Noon","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2019.01.007_bib29","first-page":"829","article-title":"Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy","volume":"186","author":"Morgan","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.eururo.2009.05.008","article-title":"Complications following radical cystectomy for bladder cancer in the elderly","volume":"56","author":"Froehner","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib31","first-page":"1634","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JOP.2011.000480","article-title":"Adjuvant intravesical bacillus calmette-gu\u00e9rin therapy and survival among elderly patients with non-muscle-invasive bladder cancer","volume":"9","author":"Spencer","year":"2013","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clgc.2019.01.007_bib33","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.eururo.2014.05.033","article-title":"The effect of age on the efficacy of maintenance bacillus Calmette-Gu\u00e9rin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911","volume":"66","author":"Oddens","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib34","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ijc.28716","article-title":"Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer","volume":"135","author":"Goossens-Laan","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2019.01.007_bib35","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1002\/cncr.27587","article-title":"The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm?","volume":"118","author":"Thomas","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.01.007_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.euo.2018.03.005","article-title":"Systematic review of comorbidity and competing-risks assessments for bladder cancer patients","volume":"1","author":"Williams","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2019.01.007_bib37","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bju.12566","article-title":"Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base","volume":"114","author":"Nielsen","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2019.01.007_bib38","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1002\/cncr.28235","article-title":"Higher surgeon and hospital volume improves long-term survival after radical cystectomy","volume":"119","author":"Kulkarni","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.01.007_bib39","first-page":"1695","article-title":"Impact of hospital and surgeon volume on in-hospital mortality from radical cystectomy: data from the health care utilization project","volume":"173","author":"Konety","year":"2005","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib40","first-page":"1385","article-title":"The regionalization of radical cystectomy to specific medical centers","volume":"174","author":"Hollenbeck","year":"2005","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib41","first-page":"2103","article-title":"Trends in regionalization of inpatient care for urological malignancies, 1988 to 2002","volume":"178","author":"Cooperberg","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib42","first-page":"424","article-title":"The association between mortality and distance to treatment facility in patients with muscle invasive bladder cancer","volume":"199","author":"Ryan","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.01.007_bib43","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2014.56.3452","article-title":"American Society of Clinical Oncology policy statement on Medicaid reform","volume":"32","author":"Polite","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.01.007_bib44","first-page":"72","article-title":"Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007","volume":"185","author":"Fedeli","year":"2011","journal-title":"J\u00a0Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319300187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319300187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:31:34Z","timestamp":1761564694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319300187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1558767319300187"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.01.007","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}